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Current treatment goals in heart failure (HF) aim to improve both survival and quality of life (QoL) of patients. In this brief
communication, we reviewed randomized controlled trials that assessed the impact of pharmacological treatment on QoL, and we discussed
some methodological limitations of QoL assessment in HF. Studies that assessed QoL with a disease-specific questionnaire were included.
We found that at present there is a paradox in HF treatment. Life prolonging therapies, such as angiotensin-converting-enzyme-inhibitors, and
angiotensin receptor blockers improve modestly or only delay the progressive worsening of QoL in HF. Treatment with beta blockers does
not affect QoL in any way. However, this neutral effect of beta blockers may also be due to some methodological limitations, such as the
small number of patients included in beta blocker trials or the short duration of follow-up. Disease-specific questionnaires may also have
some limitations, e.g. are not sensitive enough to detect small changes in QoL. On the other hand, therapies that significantly improve QoL in
HF (e.g. inotropic agents) do not seem beneficial in relation to survival. We conclude that QoL in HF remains an open field, in which new
therapies but also clarification of methodology is required. In the mean time, the use of life prolonging therapies appears as a safe measure to
modestly improve or maintain QoL.
© 2007 Elsevier Ireland Ltd. All rights reserved.Keywords: Quality of life; Heart failure; Drug therapyQuality of life (QoL) is a complex concept that en-
compasses physical, psychological and social domains of
health [1]. QoL is a “personal perception”, denoting the way
individual patients feel about their health status. Patients
with heart failure (HF) experience severe impairment in all
domains of QoL [2]. Thus, improvement of patients' QoL
has become of prime importance in achieving treatment
goals [3]. However, at present, confusion exists with regard
to the best measure of assessing QoL in HF, and clinical trials
incorporate measures from simple New York Heart Associ-
ation (NYHA) class, exercise tolerance, symptom ques-
tionnaires, or the complex QoL questionnaires. Nevertheless,⁎ Corresponding author. Tel.: +31 50 363 86 59; fax: +31 50 363 24 06.
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doi:10.1016/j.ijcard.2007.01.044QoL questionnaires, especially disease-specific are consid-
ered the measurement of election, as they focus on all
domains relevant for QoL. Currently, two disease-specific
QoL questionnaires are used most often in HF, the Minnesota
Living with Heart Failure questionnaire (MLHF) [3], and the
Quality of Life with Heart Failure questionnaire (QLHF) [4].
However, findings on QoL (as assessed by these question-
naires) with different classes of medication yielded contro-
versial results. Modest benefits in QoL at ≤1 year follow-up
were reported with the angiotensin-converting-enzyme-
inhibitor (ACEI) enalapril (on top of diuretics/digitalis) in
symptomatic HF patients, but not in asymptomatic patients
with left ventricular systolic dysfunction in the SOLVD
study [5]. In contrast, no significant difference in physical
activity, psychological distress or life satisfaction was
reported with enalapril in the CONSENSUS trial [6].
408 D. Dobre et al. / International Journal of Cardiology 125 (2008) 407–409In Val-HeFT trial, the results are more promising. Overall,
when added on top of various background therapies, the
angiotensin receptor blocker (ARB) Valsartan slows the
progressive worsening of QoL. Moreover, when added on
top of an ACEI, Valsartan significantly improves QoL [7].
However, it is of notice that despite large sample size (3000
patients) a significant difference in QoL between Valsartan
and placebo becomes evident after 20 months of follow-up.
So, what can we conclude from these results? Certainly the
study gives hope that medication that improves survival and
morbidity in HF has also a positive effect on QoL. However,
if judged critically, the effect on QoL becomes evident in
long term follow-up, which for many patients with HF may
be too late.
Prescription of a β-blocker on top of an ACEI has not
shown a significant improvement in QoL (as assessed mostly
by MLHF), although most trials reported a trend for a better
QoL in patients receiving a β-blocker [8]. So why would a
β-blocker not improve significantly QoL when added on top
of ACEI/diuretics/digitalis, while its benefits on mortality
and morbidity are now clearly established? Some may argue
that β-blockers have more side effects than ARBs, especially
during the initiation of therapy [9]. Others have blamed the
MLHF questionnaire, as not being sensitive enough to cap-
ture small changes in QoL [10]. However, more methodo-
logical issues are to be discussed when interpreting these
results. First, the Val-HeFT trial included more than 3000
patients, while the largest β-blocker trial (MERIT-HF) in-
cluded only 741 patients in the QoL sample [11]. When we
added up all the patients included in the QoL samples of β-
blocker trials, we reached approximately 2000 patients, still
much less than the number included in the single Val-HeFT
trial [8]. It could be therefore that the β-blocker trials did not
have enough power to detect a significant effect on QoL. The
second important difference is the follow-up of the patients. In
Val-HeFT, patients have been followed-up for an average of
23 months, while in the β-blocker trials patients have been
followed up for an average of 3 months, 6 months, 12 months
(MERIT HF) or a max of 18 months (MDC trial) [12] .
Other classes of medication, such as inotropic agents
(Vesnarinone in high dose) on top of ACEI/digoxin/diretics
have shown to improve significantly QoL in short term
(2 months), however at the risk of increased mortality [13].
While some patients with HF would be willing to accept
therapies that improve their QoL even at the risk of short-
ening life, this is a very controversial topic [14]. Neverthe-
less it should be acknowledged that prognosis is not the
major concern in very elderly, those with refractory symp-
toms for whom transplantation is not an option, or in indi-
viduals with terminal malignancy.
Device therapy on top of standard medication has shown
to improve both prognosis and QoL in advanced HF, but its
indication remains limited to a certain segment of patients
with HF [15]. Finally, some disease management programs
have shown also a significant improvement on QoL, but
others presented neutral results [16].HF is a progressive disease, and QoL deteriorates grad-
ually after the diagnosis [17]. In this context, it is hard to
have clear expectations with respect to the impact of medi-
cation on QoL. Given the course of the disease, slowing of
progressive worsening of QoL or a modest improvement in
QoL may be the ideal. On the other hand, patients expect a
timely and clear improvement in their QoL. The aim of
pharmacological treatment is in fact to improve QoL, al-
though QoL is not a full criterion to evaluate the effects of
medication.
Improvement of QoL in HF remains therefore an open
field, in which new therapies but also clarification of meth-
odology is required. In the mean time, the use of life pro-
longing therapies appears as a safe measure to modestly
improve or maintain QoL.
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